Five Prime Therapeutics Announces Second Quarter 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- S&P 500, Dow on course for slim gains at open as Iran tensions clash with AI optimism
- Oil prices fall after hitting over one-month high; traders weigh supply risks
- Dell again lifts annual forecasts as AI demand powers record results
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
- Uber stock gains 2% as tech giant cuts 3,300 jobs in major restructuring
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Gap taps Coach architect Reed Krakoff for $29.95-$498 handbag line
- S&P Global shares rise on report of possible CapIQ spinoff
Five Prime Therapeutics (FPRX) Tops Q2 EPS by 30c
August 8, 2018 4:47 PM EDTFive Prime Therapeutics (NASDAQ: FPRX) reported Q2 EPS of ($0.99), $0.30 better than the analyst estimate of ($1.29). Revenue for the quarter came in at $7.58 million versus the consensus estimate of $10.34 million.
For earnings history and earnings-related data on Five Prime Therapeutics (FPRX) click here.
... More